Affiliation:
1. National Heart and Lung Institute Imperial College London London UK
2. British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care University of Cambridge Cambridge UK
3. Heart and Lung Research Institute University of Cambridge Cambridge UK
4. William Harvey Research Institute, NIHR Barts Biomedical Research Centre Queen Mary University of London London UK
5. Barts Heart Centre, St Bartholomew's Hospital Barts Health NHS Trust London UK
6. National Institute for Health and Care Research Blood and Transplant Research Unit in Donor Health and Behaviour University of Cambridge Cambridge UK
7. British Heart Foundation Centre of Research Excellence University of Cambridge Cambridge UK
8. Health Data Research UK Cambridge Wellcome Genome Campus and University of Cambridge Cambridge UK
9. Medical Research Council Biostatistics Unit University of Cambridge Cambridge UK
Abstract
AbstractAimsObservational evidence suggests associations between sex hormone levels and heart failure (HF). We used sex‐specific genetic variants associated with androgenic sex hormone profiles to investigate the causal relevance of androgenic sex hormone profiles on cardiac structure and function and HF using Mendelian randomization (MR).Methods and resultsSex‐specific uncorrelated genome‐wide significant (P < 5 × 10−8) variants predicting sex hormone‐binding globulin (SHBG), total testosterone, and bioavailable testosterone were extracted from summary statistics of genome‐wide association study (GWAS) on 425 097 participants in the UK Biobank. Sex‐specific gene–outcome association estimates were computed for left ventricular ejection fraction (LVEF), left ventricular end‐diastolic and end‐systolic volumes (LVEDV and LVESV, respectively), left ventricular stroke volume (LVSV), cardiac index, and cardiac output in 11 528 female and 14 356 male UK Biobank Imaging Study participants and for incident or prevalent HF in an external cohort of 47 309 cases and 930 014 controls. Inverse‐variance weighted MR was the primary analysis method. In females, higher genetically predicted bioavailable testosterone was associated with lower LVEDV [β per nmol/L = −0.11 (−0.19 to −0.03), P = 0.006], lower LVESV [β = −0.09 (−0.17 to −0.01), P = 0.022], lower LVSV [β = −0.11 (−0.18 to −0.03), P = 0.005], lower cardiac output [β = −0.08 (−0.16 to 0.00), P = 0.046], and lower cardiac index [β = −0.08 (−0.16 to −0.01), P = 0.034] and a higher risk of HF [odds ratio 1.10 (1.01–1.19), P = 0.026] on external validation analysis in larger scale, sex‐adjusted GWAS data. Higher genetically predicted SHBG was associated with higher LVEDV [β per nmol/L = 0.17 (0.08–0.25), P = 2 × 10−4], higher LVESV [β = 0.13 (0.05–0.22), P = 0.003], and higher LVSV [β = 0.18 (0.08–0.28), P = 2 × 10−4]. In males, higher genetically predicted total and bioavailable testosterone was associated with lower LVESV [β = −0.07 (−0.12 to −0.02), P = 0.007] and LVEF [β = −0.11 (−0.18 to −0.04), P = 0.003], respectively.ConclusionsThis study supports a causal effect of pro‐androgenic sex hormone profiles in females on adverse markers of left ventricular structure and function typically associated with HF with preserved ejection fraction and with HF. There was weaker evidence of association in males.
Funder
British Heart Foundation
NIHR Cambridge Biomedical Research Centre
Health Data Research UK
NIHR Imperial Biomedical Research Centre
Subject
Cardiology and Cardiovascular Medicine